🚨 New insights from EHJ 2025! 🚨
In statin-treated patients undergoing PCI, inflammation (hsCRP ≥2 mg/L)—not elevated LDL-C—was the strongest predictor of MACE at 1 year 🔥🧪
📊 Bay et al. show that residual inflammatory risk carries a 1.8x higher hazard for adverse events, while LDL-C alone showed no independent risk 💥
🧠 Time to shift focus beyond lipids: consider anti-inflammatory therapies, remnant cholesterol, and Lp(a) in risk stratification 🩺🎯
📖 Read the study ➡️ https://doi.org/10.1093/eurheartj/ehaf196
#Cardiology #Inflammation #ResidualRisk #PCI #Statins #PrecisionMedicine
